This record was last updated January 16, 2024 (before its estimated August 2025 completion). Its status may not reflect the trial's current state.
Summary
Mucocutaneous leishmaniasis is endemic in the central region of Brazil and other countries worldwide. The standard treatment with meglumine antimoniate has a high rate of important adverse effects. This interventional study consists in a randomized clinical trial to access efficacy and safety of the association of miltefosine and pentoxifylline compared to meglumine antimoniate and pentoxifyline.
Protocol Amendment History
8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2015-08-20; most recent amendment 2024-01-11.
Status change: Recruiting → Active, Not Recruiting2022-05-23